Tag: Biosimilars

Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans

Fitch said the ‘Positive’ outlook of the Company’s credit rating reflects its expectation of a sustained reduction in Biocon Limited's financial leverage

This agreement enables Samsung Bioepis to launch SB15 in the United Kingdom (UK) from January 2026, in the rest of Europe from April 2026

The Budget’s focused push on biologics and biosimilars, backed by a dedicated biopharma innovation network, was described by Matai as positioning India strongly for the next wave of complex, high-value therapies

This integration will enable Biocon to leverage the combined strengths of its biosimilars and generics operations across more than 120 countries

The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025

The FDA released a new draft guidance proposing major changes to simplify biosimilarity studies and reduce unnecessary clinical testing

The 2025 event to explore how Indian pharmaceutical companies can capture new growth in generics and biosimilars while navigating competition and regulatory complexities

Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited shares his views on the current market trends and growth prospects of Indian biosimilars industry, company’s key offerings, ongoing initiatives, and future plans

The Cover Story analyses the potential impact of significant uncertainty due to the proposed reciprocal tariffs with insights from Vishal Dhikale, Associate Vice President, Avalon Consulting. Read interview of Puneeth Kumar KT, Business Director for Planetary Health Biosolutions, Novonesis South Asia and Expert Insights by Mahesh Ramanujam, President & CEO, Global Network for Zero; and Dr Vidhi Bhanushali, CEO and Co-founder, scanO.